Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Themes AI

AMD Enters Healthcare AI Race with $20M Absci Investment, Challenging Nvidia’s Dominance

by Team Lumida
January 8, 2025
in AI
Reading Time: 3 mins read
A A
0
white and green hard disk drive

Photo by Olivier Collet on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com
• AMD invests $20M in Absci through private investment in public equity
• Partnership aims to optimize AI solutions and reduce hardware costs
• Absci to transition from Nvidia to AMD GPUs for drug discovery
• Marks AMD’s first strategic move into healthcare AI computing

What Happened?

AMD has announced a $20 million investment in Absci, a Washington-based AI drug discovery company, marking its first strategic entry into the healthcare AI sector. The partnership includes an equity stake and focuses on optimizing AI solutions while reducing hardware costs. Absci, currently using over 470 AI chips (mostly Nvidia GPUs), will begin transitioning some of its drug discovery workloads to AMD’s hardware.

Why It Matters?

This move represents AMD’s strategic challenge to Nvidia’s dominance in the healthcare AI sector, following Nvidia’s $50M investment in Recursion Pharmaceuticals last year. The partnership addresses the growing computational demands of AI-driven drug discovery, where compute costs have become a significant factor. For Absci, with its 160 employees and $567M total funding, the partnership offers potential cost reductions in AI model inference and access to specialized hardware development.

What’s Next?

Watch for Absci’s transition to AMD GPUs and its impact on operational efficiency. Key indicators will include the success of hardware and software developments specifically tailored for healthcare AI applications. Absci’s clinical trial results for inflammatory bowel disease treatment in the second half of the year could validate the partnership’s effectiveness. AMD’s expansion into other vertical markets and potential similar investments should be monitored, as this marks the beginning of their industry-specific AI strategy. The competition between AMD and Nvidia in the healthcare AI sector could reshape the market dynamics for specialized AI computing solutions.

Source
Previous Post

Novo Nordisk Expands AI Drug Discovery Partnership with Valo Health in $4.8B Deal

Next Post

Apple Defends Siri’s Privacy Practices Following $95M Settlement

Recommended For You

Trump Says the US Could Let Nvidia Sell Blackwell Chips to China in ‘Two Years or Three Years,’ Calling the H200 ‘Semi-Obsolete’ as Congress Moves to Bar Sales for 18 Months

by Team Lumida
1 day ago

Trump said Nvidia could sell Blackwell chips to China in two or three years, as senators push the AI Overwatch Act to bar such sales for at least...

Read more

Intel Signs Its First Outside Customer for 18A Chips and Names Microsoft as Its First Public Customer for EMIB Packaging, After Losing More Than Half Its Value Since September

by Team Lumida
1 day ago
Intel Surges 5%, SK Hynix Up 3% on Reports of U.S. Memory Chip Manufacturing Deal to Serve Nvidia and AI Demand

Intel CEO Lip-Bu Tan said the company signed its first outside customer for 18A chips and named Microsoft as its first public EMIB packaging customer.

Read more

China’s Military Is ‘Actively Soliciting’ Nvidia’s Most Advanced Chips for AI-Enabled Military Capabilities, a Congressional Commission Says in Its 2026 Report

by Team Lumida
2 days ago

A congressional commission said China’s military is seeking advanced Nvidia chips and evading export controls, including via data centers in Malaysia.

Read more

Bipartisan Push to Attach AI Chip Export Limits to the December NDAA Gains Steam After the Huang Affair, With Schumer, Jeffries and Speaker Johnson Backing the AI Overwatch, MATCH and Chip Security Acts

by Team Lumida
2 days ago

Lawmakers from both parties are pushing three chip export bills into the December defense bill after Jensen Huang’s resignation, but time is short.

Read more

Banks Pause a $480 Million Nvidia GPU Loan to Aolani Cloud Tied to ByteDance After New US Licensing Rules for Malaysia and Singapore Data Centers

by Team Lumida
3 days ago
ByteDance Is Buying Custom Chips From Taiwan Because It Cannot Buy Nvidia’s, Which US Rules Permit

Banks paused or reconsidered a $480 million Aolani Cloud loan for Nvidia GPUs tied to ByteDance after new US licensing rules, Bloomberg reported.

Read more

Commerce and Justice Say They Began Investigating Nvidia Partner Megaspeed in 2024, as Critics Ask Why It Kept Getting Chips After Nvidia’s ‘No Sell’ Listing

by Team Lumida
3 days ago

Commerce and Justice said they opened export-control probes into Megaspeed in 2024 and inspected it in June 2025, as critics question how it kept buying chips.

Read more

Nvidia Warns Chip Buyers That the Remote Access Security Act Could Expose Them to US ‘Legal Action’ and Caps Sales to Clouds Renting Over 50% of GPUs to Chinese Firms

by Team Lumida
3 days ago

Nvidia cautioned customers that the proposed Remote Access Security Act could bring US legal action over Chinese cloud access to its chips, CNBC reported.

Read more

Anthropic’s IPO Could Hand 300-Plus Investors a Windfall, With a $1.33 Trillion Valuation About 38% Above Its $965 Billion May Round

by Team Lumida
4 days ago

Anthropic’s IPO, expected to value it at $1.33 trillion or more, is set to reward over 300 investors, from Spark and Menlo to Amazon and Alphabet.

Read more

Commerce Moves to Close the Offshore Data-Center Loophole for Chinese AI Firms and Requires Licenses for Chip Exports to Five Countries, Its First Policy Response to the Nvidia Scandal

by Team Lumida
4 days ago

Commerce issued a rule curbing Chinese firms’ offshore access to Nvidia compute and requiring chip-export licenses for five higher-risk countries.

Read more

Trump Administration Plans to Name Nvidia, OpenAI and More Than Two Dozen AI Firms ‘National Champions’ as the BAI AI ETF Sits 33% Below Its June Record

by Team Lumida
4 days ago
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears

The Trump administration plans to name more than two dozen AI firms, including Nvidia and OpenAI, US national champions, the WSJ reported.

Read more
Next Post
apple logo on blue surface

Apple Defends Siri's Privacy Practices Following $95M Settlement

A building with a sign on the side of it

Uniqlo Parent Fast Retailing Posts Strong Q1 Results, Driven by Global Expansion

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Private Equity Promised to Slow Its Recruiting of Junior Bankers. Citi Says It Hasn’t Happened

Private Equity Promised to Slow Its Recruiting of Junior Bankers. Citi Says It Hasn’t Happened

October 7, 2026

Trump’s EPA Moves to Ease Oil Well Methane Rules, Claiming $45 Billion in Savings and 210 Million Extra Barrels Through 2050

October 27, 2026
The Iran War’s Invisible Casualty: A Helium Crisis That Could Cripple AI Chips and MRI Scanners

US Bombs Iran for Ninth Straight Day as Hormuz Standoff Deepens, Brent Crude Tops $90

July 20, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018